VANCOUVER, BRITISH COLUMBIA--(Marketwire - Oct. 7, 2008) - Allon Therapeutics Inc. (TSX:NPC) announced today that it has been granted a United States patent covering composition, delivery and method of use for new neuroprotective drugs comprised of combinations of peptides from the Company's two proprietary technology platforms, activity-dependent neuroprotective protein (ADNP) and activity-dependent neurotrophic factor (ADNF).
